Calcineurin inhibitors revisited: A new paradigm for COVID-19?
Braz. j. infect. dis
; 24(4): 365-367, Jul.-Aug. 2020. tab
Article
em En
| LILACS, ColecionaSUS
| ID: biblio-1132459
Biblioteca responsável:
BR1.1
ABSTRACT
Abstract The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVID-19 are all investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment for COVID-19, based on experiences seen in solid organ transplant recipients who suffered from COVID-19.
Palavras-chave
Texto completo:
1
Índice:
LILACS
Assunto principal:
Pneumonia Viral
/
Infecções por Coronavirus
/
Inibidores de Calcineurina
Limite:
Humans
Idioma:
En
Revista:
Braz. j. infect. dis
Assunto da revista:
DOENCAS TRANSMISSIVEIS
Ano de publicação:
2020
Tipo de documento:
Article